Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over a 5-year period.
Patients with Rheumatoid Arthritis and started treatment with adalimumab in a normal clinical setting according to the label were documented. The follow-up observation period was for 5 years and focused on safety information and maintenance of efficacy during the normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.
Inclusion Criteria:
Exclusion Criteria:
Blankenburg/Hart, 38889, Germany
Moenkeberg, 24248, Germany
Raststatt, 76437, Germany
Thum-Jahnsbach, 9419, Germany
Tischenreuth, 95643, Germany
Ueberlingen-Nussdorf, 88662, Germany
Uhlstaedt-Kirchhasel, 07407, Germany
Vogelsang-Gommern, 39245, Germany
Waldbronn, 76337, Germany
Weiden I.d. Oberpfalz, 92637, Germany